On September 25, 2024, Pfizer Inc. (NYSE: PFE) announced the voluntary global withdrawal of OXBRYTA® (voxelotor), its treatment for sickle cell disease (SCD), due to safety concerns. This decision follows a review of clinical data that raised alarms about the drug’s safety, particularly the increased risk of vaso-occlusive crises and fatal events. Pfizer concluded that […]